First coeliac disease vaccine moves forward in expanded clinical programme

Some of the $20 million that the US startup ImmusanT raised late last year in a Series A financing is being put to use with the start of an expanded international clinical programme for Nexvax2, its ground-breaking therapeutic vaccine for coeliac disease.One of the new placebo-controlled Phase I trials will see around 84 patients enrolled across four sites in Australia and New Zealand, in which induction of tolerance in individuals on a gluten-free diet will be assessed at multiple ascending doses.

Some of the $20 million that the US startup ImmusanT raised late last year in a Series A financing is being put to use with the start of an expanded international clinical programme for Nexvax2, its ground-breaking therapeutic vaccine for coeliac disease.One of the new placebo-controlled Phase I trials will see around 84 patients enrolled across four sites in Australia and New Zealand, in which induction of tolerance in individuals on a gluten-free diet will be assessed at multiple ascending doses.

The second new trial, in around 30 adults at four sites in the US, will look at safety, tolerability and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By 

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By 

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By 

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

More from Therapeutic Category

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By 

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By 

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.